Impact of pre-existing drug resistance on risk of virological failure in South Africa.

Objectives: There is conflicting evidence on the impact of pre-existing HIV drug resistance mutations (DRMs) in patients infected with non-B subtype virus.

Methods: We performed a case-cohort substudy of the AIDS Drug Resistance Surveillance Study, which enrolled South African patients initiating first-line efavirenz/emtricitabine/tenofovir. Pre-ART DRMs were detected by Illumina sequencing of HIV pol and DRMs present at <20% of the viral population were labelled as minority variants (MVs).

Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations.

Background: The aim was to analyse trends in clinically relevant resistance to first-line antiretroviral drugs in Spain, applying the Stanford algorithm, and to compare these results with reported Transmitted Drug Resistance (TDR) defined by the 2009 update of the WHO SDRM list.

Methods: We analysed 2781 sequences from ARV naive patients of the CoRIS cohort (Spain) between 2007-2011. Using the Stanford algorithm "Low-level resistance", "Intermediate resistance" and "High-level resistance" categories were considered as "Resistant".

[HIV infection and chronic inflammation: is the bacterial translocation the underlying cause?].

Currently, non-AIDS comorbidities (cardiovascular disease, non-AIDS-related cancers, liver disease, osteoporosis, etc.) have become an important cause of morbimortality in patients with human immunodeficiency virus type 1 (HIV-1) infection. The elevation of plasma markers of inflammation has been associated with the development of cardiovascular disease and death from all causes.